Results 71 to 80 of about 329,411 (267)

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Outcome of fetal pyelectasis diagnosed antenatally

Journal of Obstetrics and Gynaecology, 2005
Renal pelvis dilatation is a common anomaly detected at the 20-week anomaly scan. The aim of this study was to evaluate the postnatal outcome of fetal pyelectasis in an unselected obstetric population. This was a retrospective study of fetal pyelectasis detected at midtrimester anomaly scan.
G, Ahmad, P, Green
openaire   +2 more sources

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Case Series of Adverse Pregnancy Outcomes Associated with Oropouche Virus Infection

Viruses
The Oropouche virus (OROV) is an arbovirus (Peribunyaviridae: Orthobunyavirus) that traditionally causes febrile outbreaks in Latin America’s Amazon region. Previously, OROV was not associated with severe pregnancy outcomes. During the 2022–2024 outbreak
Daniele Barbosa de Almeida Medeiros, Juarez Antônio Simões Quaresma, Raimunda do Socorro da Silva Azevedo, Ana Cecilia Ribeiro Cruz, Sandro Patroca da Silva, Arnaldo Jorge Martins Filho, Bruno Tardelli Diniz Nunes, Lucas Rafael Santana Pinheiro, Jorge Rodrigues de Sousa, Jannifer Oliveira Chiang, Lívia Carício Martins, Consuelo Silva Oliveira, Ivy Tissuya Essashika Prazeres, Daniele Feitas Henriques, Camille Ferreira Oliveira, Valéria Lima Carvalho, Clarice Neuenschwander Lins Morais, Bartolomeu Acioli-Santos, Keilla Maria Paze Silva, Diego Arruda Falcão, Mayara Matias de Oliveira Marques Costa, Eduardo Augusto Duque Bezerra, Ana Márcia Drechsler Rio, Neijla Cristina Vieira Cardoso, Juliana Carla Serafim da Silva, Simone Gurmão Ramos, Erika Cavalcante Maranhão, José Lancart de Lima, Pedro Fernando da Costa Vasconcelos, Bruno Issao Matos Ishigami, Lívia Medeiros Neves Casseb   +30 more
doaj   +1 more source

Folic acid in pregnancy and fetal outcomes

Journal of Obstetrics and Gynaecology, 2008
Folic acid has become recognised as an important nutrient during pregnancy. The following review highlights the significant developments in recognising folic acid importance in fetal development.
Y I, Goh, G, Koren
openaire   +2 more sources

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Safety of Onabotulinumtoxin-A for Chronic Migraine During Pregnancy and Breastfeeding: A Narrative Review

Toxins
Onabotulinumtoxin-A (onabotA) is a neurotoxin widely used for several indications, including chronic migraine (CM) preventive treatment, due to its well-demonstrated efficacy, tolerability, and safety.
Antonio Russo, Luigi Francesco Iannone, Ilaria Orologio, Veronica Rivi, Alberto Boccalini, Flavia Lo Castro, Marcello Silvestro, Simona Guerzoni   +7 more
doaj   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Influenza vaccination and fetal and neonatal outcomes

Expert Review of Vaccines, 2013
As pregnant women are considered a high-risk group for severe influenza illness, current recommendations advise vaccination of all pregnant women with inactivated influenza vaccine. Nevertheless, rates of maternal influenza vaccination have historically been low, possibly reflecting ongoing concerns about vaccine safety. Until recently, the majority of
Deshayne B, Fell, Linda, Dodds, Noni E, MacDonald, Victoria M, Allen, Shelly, McNeil   +4 more
openaire   +2 more sources

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source